Onesource Specialty Pharma Stock

Onesource Specialty Pharma EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Onesource Specialty Pharma (ONESOURCE.NS) as of Jul 20, 2026 is 70.31. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -86.43 — a change of -181.35% (higher).

EV/EBIT

70.31

YoY

-181.35%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Onesource Specialty Pharma is 2026 70.31 . EV/EBIT (Enterprise Value to EBIT) of Onesource Specialty Pharma was 2025 -86.43 . It decreases by -181.35% higher compared to the previous year.

The Onesource Specialty Pharma EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2023
0.00 base
Jan 1, 2024
0.00 base
Jan 1, 2025
102.82 base
Jan 1, 2026 (e)
58.33 base
YEARPRICE-TO-EBIT
2026 est 58.33
2025 102.82
2024 -
2023 -
Access this data via the Eulerpool API
Get Free API Key

Onesource Specialty Pharma Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Onesource Specialty Pharma's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Onesource Specialty Pharma's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Onesource Specialty Pharma's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Onesource Specialty Pharma grows earnings faster than its peers.

Onesource Specialty Pharma Stock analysis

What does Onesource Specialty Pharma do? Onesource Specialty Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Onesource Specialty Pharma stock

EV/EBIT (Enterprise Value to EBIT) of Onesource Specialty Pharma is 70.31 in 2026.

Access this data via the Eulerpool API
Get Free API Key

Valuation — Onesource Specialty Pharma

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueEV/EBITForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Onesource Specialty Pharma